Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2022-05-19 Director's Dealing
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2022-05-19 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes detailed information about a merger agreement, issuance of shares, lock-up agreements, contingent value rights, registration rights, and other related corporate actions. It also includes a notice of non-compliance with Nasdaq listing rules and unregistered sales of equity securities. The document is not a full annual or quarterly report, nor is it a transcript, proxy statement, or remuneration report. It primarily announces a significant corporate transaction and related financing and governance matters. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it covers financing activities and capital structure changes related to the merger and issuance of securities. The document length and detail confirm it is not a brief announcement or a simple notice, but a substantive current report on a material definitive agreement and related capital transactions.
2022-05-17 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-16 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 16, 2022, by Aprea Therapeutics, Inc. It announces the issuance of financial results for the three months ended March 31, 2022, via a joint press release attached as Exhibit 99.1. It also announces the entry into a merger agreement and completion of related transactions. The document explicitly states it is a Current Report on Form 8-K, which is used for unscheduled material events or corporate changes. The content includes a press release with financial results and merger information but does not contain the full financial statements or detailed financial analysis itself. The document is not a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER) but rather a regulatory filing announcing these events. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (6695 characters) and content support this classification with high confidence.
2022-05-16 English
10-K/A
Annual Report FY 2021
2022-05-02 English
10-K
Annual Report FY 2021
2022-03-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.